Sugi Predict

Sugi Predict / Compounds / SCHEMBL2135751

SCHEMBL2135751

SCHEMBL2135751

Cc1cccn2cc(C(=O)Nc3nc4cc(-c5ccccc5)ccc4[nH]3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 2/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ NPC1 O15118 10/20 0.42
▸ RAB9A P51151 10/20 0.42
▸ SMN1; SMN2 Q16637 6/20 0.42
▸ TP53 P04637 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ PKM P14618 2/20 0.41
▸ MAOB P27338 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ OPRK1 P41145 1/20 0.40
▸ KLF5 Q13887 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2135031 0.93 NPC1 (0.47) ABL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2134001 0.92 NPC1 (0.45) ABL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2133207 0.91 NPC1 (0.38) ABL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2138344 0.90 MTOR (0.41) KDM4EALDH1A1MEN1KMT2ANPC1
SCHEMBL2139061 0.89 ABL1 (0.48) ABL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2133800 0.89 NPC1 (0.39) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL2135866 0.89 SMN1; SMN2 (0.41) KDM4EALDH1A1MEN1KMT2ANPC1
SCHEMBL10225451 0.89 NPC1 (0.39) ABL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2135220 0.88 NPC1 (0.39) ABL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2135556 0.87 NPC1 (0.40) ABL1KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US claimed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US disclosed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US disclosed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US disclosed
WO-2010126745-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP ABL1 586/4885KDM4E 2967/4885ALDH1A1 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.